Stock Evaluator: Structure Therapeutics Inc. (GPCR)

Structure Therapeutics Inc. GPCR

$54.51 -0.19 -0.35%
August 14, 2026 4:00:00 PM EST November 10, 2021 Volume: 555,884
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Commentary & Analysis


Financial Summary

Share Statistics GPCR Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $3,887.1 $587.7 63%
Shares Out (Mil) 72.7 44.5 56%
Institutional Ownership 95.9% 84.6% 68%
Float (Mil) 55.1 46.8 49%
Beta -1.51 0.69 1%
Avg Daily Volume (000s) 592 361 60%
Price Change
(52-week)
184.5% 66.7% 96%
Growth GPCR Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 6.7% na
Net Income (5yr) (54.8%) (1.4%) 6%
EPS (5yr) 20.9% 14.9% 70
Dividends (5yr) na 0.0% na
Cash Flow (5yr) 34.0% (14.9%) 88%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 9 9 7
Current EPS ($0.218) ($1.548) ($2.115)
Month Ago EPS ($0.167) ($1.306) ($1.934)
# Rev Up 0 0 0
# Rev Down 1 1 1
Three Months Ago EPS ($0.125) ($1.217) ($1.902)
Year/Year Chg (85.1%) (35.1%) (36.0%)
Financials GPCR Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $276 na
Net Income (TTM) (Mil) ($215) ($11) 6%
EPS (TTM) ($3.219) ($0.700) 11%
Operating Cash Flow (TTM) (Mil) ($220) ($6) 3%
Net Cash Flow (TTM) (Mil) $126 $5 80%
Long-Term Debt (Q1) (Mil) $4 $6 23%
Enterprise Value (Q1) (Mil) $2,381 $309 53%
Valuation GPCR Industry
Median
Percentile
(All Stocks)
P/B 2.87 2.89 62%
P/E na 17.2 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.1 na
Ratios GPCR Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.5% na
Net Margin na (2.3%) na
ROA (19.2%) (22.5%) 21%
ROE (20.2%) (19.8%) 23%
Liabilities to Assets 5.0% 32.4% 2%
F-Score 3 3 18%

Passing Stock Screens

As of 8/14/2026, from a list of 60 stock screening strategies, GPCR meetings the criteria of 2 screen: